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Low-cost integrated biosensing platform based on SiN nanophotonics for biomarker 
detection in urine  
D. Martensa,b, P. Ramirez-Priegoc, M. S. Muriba,b, A.A. Elamind, A.B. Gonzalez-Guerreroc, M. Stehrd, 
F. Jonasd, B. Antone, N. Hlawatsche, P. Soetaertf, R. Vosg, A. Stasseng, S. Severig, W. Van Royg, R. 
Bockstaelef, H. Beckere, M. Singhd, L.M. Lechugac, P. Bienstman*a,b 
We present a low-cost integrated nanophotonic lab-on-a-chip platform suitable for point-of-care (POC) biomarker analysis. 
The sensor chip included in the platform contains multiplexed Mach-Zehnder interferometers with an on-chip optical 
spectral analyser consisting of an arrayed-waveguide grating. The sensor chip is fabricated in silicon nitride material, which 
renders it compatible with consumer-electronics-grade sources and detectors, leading to the possibility of low-cost 
instrumentation.  The nanophotonic sensor chip exhibits a detection limit of 6.10-6 RIU (Refractive Index Units), which is in 
the same order of magnitude as the reported values for the evanescent wave sensors at the state-of-the-art. The sensor 
chip is biofunctionalised with specific bioreceptors and integrated in a polymer microfluidics cartridge. The POC 
instrumentation platform contains the optical excitation and read-out sub-systems and a dedicated on-board software for 
a real-time analysis of patient samples. To demonstrate the versatility of the platform, we present results both on the 
detection of an antigen related to tuberculosis directly in urine samples using a laboratory prototype and on the detection 
of a protein biomarker (CRP) related to inflammation using the integrated instrument.
Introduction 
Integrated evanescent field photonic biosensors are promising 
candidates for real-time qualitative and quantitative evaluation of 
biomolecular interactions. In these sensors, a change in the effective 
refractive index caused by the binding of an analyte to its specific 
bioreceptor, is converted into a measurable quantity, most 
commonly a resonant wavelength shift, through an integrated 
photonic transducer. Various types of sensors have been developed: 
Young and Mach-Zehnder (MZI) interferometers, bimodal sensors, 
ring resonators, photonic crystal based sensors and various others 
[1–5]. In general, evanescent wave sensors provide sensitivity, 
selectivity and versatility, which renders them applicable in a broad 
range of disciplines, ranging from medicine over food quality control 
to environmental management. Furthermore, they offer great 
potential as lab-on-a-chip devices, performing point-of-care 
measurements at an affordable cost. 
While practical applications have emerged, in many cases the 
readout of theses sensors requires either an expensive tuneable 
laser or an off-chip spectrometer, making them expensive and/or 
slow. Therefore, the instrumentation cost is typically high, rendering 
the system unfit for true point-of-care applications. We aim to 
overcome this important barrier by using a broadband light source in 
combination with an on-chip spectral filter as interrogation 
mechanism [6-8]. The filter divides the transducer spectrum into 
different wavelength channels with spatially separated output ports. 
By fitting a curve to this dataset, the central wavelength of the 
original sensor spectrum is determined with an accuracy that 
surpasses the resolution of the spectral filter itself by multiple orders 
of magnitude. 
The manuscript is structured as follows. First, we present how such 
sensor chips can be designed and fabricated using mass-fabrication-
compatible technology. Before moving on to a fully integrated 
platform with a dedicated microfluidics and readout components, 
we first characterised the performance of the sensor chip in a lab-
based prototype with in-house microfluidics. We determine the bulk 
limit-of-detection and then move further to perform biosensing 
experiments to detect Mycobacterium tuberculosis 
lipoarabinomannan (LAM) in clinical samples. After that, we move 
from a lab-based prototype to a fully integrated platform that is 
closer to commercialisation. We discuss how these silicon nitride 
based sensor chips can be integrated in a standard polymer fluidics 
cartridge, and describe in more detail the custom readout 
instrument and the associated software. Finally, this integrated 
platform is used to detect the C-reactive protein biomarker, related 
to inflammatory processes.  
Photonic sensor design 
The most important property for an integrated photonic sensor to 
enable use as a point-of-care diagnostic device is compatibility with 
a cheap read-out system, requiring no expensive components such 
as tuneable lasers or off-chip spectrometers. In our design, the 
approach is to interrogate the sensor through an off-chip broadband 
light source, an on-chip spectral filter and an off-chip camera, all of 
which are affordable within a point-of-care context. This is especially 
true for the very near-infrared wavelength range, which can be used 
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due to the choice of the sensor material. The spectral filter employed 
is an Arrayed Waveguide Grating (AWG), which is a state-of-the-art 
design in the given wavelength range (850 nm) in terms of footprint 
as well as performance [9]. 
As a sensor for this interrogation scheme, the Mach-Zehnder 
Interferometer (MZI) was selected, with one of the arms isolated 
from and the other exposed to the analyte. The main merit of this 
MZI configuration is its large design freedom, which enables tuning 
the sensitivity and the spectral period independently. The latter is 
relevant, as the characteristics of integrated spectral filters are 
typically restricted by fabrication limitations [10], and their ratio has 
a large influence on the final performance of the sensor [6]. The light 
interfacing with the chip occurs through grating couplers. At the 
input side, the grating couplers are flood-illuminated by a broadband 
light source [11]. This method allows interrogating multiple sensors 
at the same time, and as such opens the door to multiplexing. At the 
output side, the transmitted power of a large number of grating 
couplers is measured in parallel with a camera. A picture of the 
complete design of the photonic sensing circuit is shown in Fig. 1. 
 
 
Figure 1: Integrated photonic sensor circuit consisting of a MZI 
sensor read-out by an on-chip AWG spectral filter. 
The transduction mechanism is based on the evanescent field: a 
change in the environment of the exposed MZI arm, such as a binding 
event or a bulk refractive index shift, will result in a change in the 
effective refractive index of the exposed MZI arm. This, in turn, 
results in a phase shift in this arm, which causes a spectral shift in the 
whole spectrum of the MZI. This shift is tracked through continuous 
monitoring of the locations of the spectral peaks of the MZI. To 
determine the peaks of this spectrum, we illuminate the chip using a 
broadband light source. The spectrum of the sensor (Fig. 2a) is sent 
through the different channels of the spectral filter (Fig. 2b), yielding 
a discretised version of the sensor spectrum (Fig. 2c). The resolution 
of this spectrum is typically low, as it is limited by the number of 
available data points per spectral period, determined by the channel 
spacing of the on-chip spectral filter. To compensate for this 
drawback, the original spectrum is reconstructed out of the 
discretised data through fitting (Fig. 2d), and the peak of this 
reconstructed spectrum is tracked. This greatly increases the 
accuracy on the obtained peak wavelength values. This procedure is 
more elaborately described in [6]. 
 
Figure 2: Interrogation principle based on a broadband source and 
an on-chip spectral filter. 
 
The whole sensing chip contains 6 sensors, each with their MZI and 
AWG, as well as 30 output grating couplers per sensor, one for each 
of the AWG channels. The entire design fits in a chip area of less than 
6 mm x 6 mm (Fig. 3). 
 
Figure 3: Layout a sensing circuit consisting of 6 sensors, each with 
their own MZI and AWG. 
 
Sensors fabrication 
Photonic integrated circuits (PICs) sensors were fabricated based on 
the CMOS compatible SiN photonics developed at imec, using wafer-
level processing on standard 725 μm thick 200 mm Si wafers [10]. 
First a 70 nm thick SiN anti-reflective coating was deposited using 
plasma-enhanced chemical vapour deposition (PECVD) using SiH4, N2 
and NH3 at 400°C (Fig. 4). The purpose of this layer is to decrease the 
back-reflections coming from the oxide-Si interface, which would 
reduce the light incoupling efficiency of the grating couplers. 
Subsequently, a 2.3 μm thick PECVD SiO2 layer, which had been 
specifically engineered to compensate the stress level of the wafers, 
was deposited using SiH4 and N2O. The roughness of the layer was 
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reduced by applying a short chemical-mechanical polishing (CMP) 
step. On top of this oxide layer, a 220 nm thick PECVD SiN layer was 
deposited using SiH4, N2 and NH3 at 400°C. This waveguide material 
has been optimised to minimise the light propagation loss in the 
visible wavelength range [10]. Refractive indices at λ = 850 nm were 
nSiO2 = 1.48 and nSiN = 1.88 as measured by ellipsometry. 
 
Grating couplers were defined using 193 nm deep ultraviolet (DUV) 
lithography followed by a shallow etch of  110 nm depth into the SiN 
to maximise light coupling into the waveguide. A fluorine-based 
inductively coupled plasma reactive ion etching process was used to 
minimise sidewall roughness and achieve the required sidewall 
slope. Next, waveguides were defined by a separate 193 nm DUV 
lithography step and similar etch, but now the full thickness of the 
SiN layer was etched.  Following this process, a 2 μm layer of PECVD 
SiO2 was deposited and planarised by CMP. Finally sensing regions 
were defined by 365 nm i-line lithography followed by a selective 
removal of the top oxide cladding using a dry etching process 
followed by a wet etching step. 
 
 
Figure 4: Process flow for the SiN photonic chip fabrication. 
 
Evaluation of the bulk sensitivity 
Sensors were initially characterised through bulk sensing in a lab-
based setup, with equipment compatible with point-of-care sensing. 
The bulk sensing limit-of-detection (LOD) provides an excellent 
figure-of-merit as it can be compared between various sensor types 
regardless of surface biofunctionalisation. To evaluate this value, the 
sensor is exposed to different concentrations of a solution (i.e.: HCl) 
in alternation with water. An example of a resulting sensorgram, 
where 5 sensors are measured in parallel, is shown in Fig. 5.  
To determine the LOD, the following procedure was used. The shifts 
of the spectra are tracked, and the sensitivity of each sensor is 
calculated as the slope of the obtained spectral shifts as a function of 
the corresponding changes in the bulk refractive index. The minimum 
detectable wavelength shift is calculated as 3 times the standard 
deviation on the signal after transients have passed. The ratio of the 
minimum detectable wavelength shift to the sensitivity yields the 
LOD. This experiment was done multiple times, with different chips 
from different wafers. The set of experiments yielded an average 
LOD of 6.10-6 RIU, with a standard deviation of 2.10-6 RIU. This 
indicates a high reproducibility (given that we used different chips) 
as well as results competitive with most integrated photonic sensors, 
despite the low-cost read-out [6].   
 
Figure 5: Sensorgram of parallel measurement of five MZI sensors, 
where the sensors are exposed to different concentrations of HCl in 
alternation with water. 
 
LAM detection in urine (lab setup) 
Before building an integrated readout system with a dedicated 
microfluidic cartridge, we first tested the functionality of the sensor 
chip by performing LAM measurements in clinical urine samples. 
LAM is a biomarker indicative of tuberculosis (TB) infection, and we 
correlated the measurements with the disease status of the 
participants. 
To prepare the chips, anti-LAM IgM mAb molecules were covalently 
immobilised on the SiN chips using a silane route [12, 13]. Prior to 
any functionalisation, the SiN chips were cleaned in acetone, 
isopropanol, and ultrapure water. Next, the chips were exposed to 
oxygen plasma for one minute using a reactive-ion etching (RIE) 
system to terminate the surface with hydroxyl groups. Afterwards, 
the silanisation of the chips was carried out by liquid-phase 
deposition of silanes in an organic solvent [13]. The chips were placed 
in a 600 mM solution of (3-amino-propyl) tri-ethoxysilane (APTES, 
99%; Sigma–Aldrich, Steinheim, Germany) in toluene (≥99.9%, 
Sigma–Aldrich) for 15 hours in a nitrogen-filled glove-box. To wash 
off unbound APTES molecules, the chips were rinsed with toluene, 
followed by tetrahydrofuran (THF, ≥99.9%, Sigma–Aldrich). After 
drying the chips under nitrogen flow, they were cured for 30 minutes 
at 120°C, resulting in an especially strong adhesion of the APTES layer 
to the surface [13]. This way, the surface becomes modified with 
amines, allowing for the subsequent reaction with succinic anhydride 
(SA) in order to yield a carboxyl-terminated surface [12, 14]. Succinic 
anhydride (SA, ≥99.9%, Sigma–Aldrich) was used as a cross-linker 
molecule to ensure the binding of the amino group of APTES to the 
NH2 groups of the anti-LAM by providing carboxylic groups at the 
surface. For this purpose, the chips were placed overnight in a 
solution of 800 mM of SA in acetonitrile (ACN) (anhydrous, 99.8%, 
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Sigma–Aldrich), after which they were rinsed with pure acetonitrile 
and dried under nitrogen gas. The amine-terminated surface reacts 
with one of the two carbonyl groups of the SA molecules, causing the 
anhydride ring to open and to form a covalent bond with this 
carbonyl group. The other carbonyl group is released to form a free 
carboxylic acid-terminated surface [15]. The anti-LAM molecules 
were covalently coupled to the carboxyl-terminated SiN chips using 
the zero-length crosslinker 1-ethyl-3-3-dimethylaminopropyl-
carbodiimide (EDC) in 2-[N-morpholino]-ethannesulphonic acid 
(MES) buffer at room temperature. In order to lower the effect of 
non-specific binding, the chips were blocked with 0.5 mg/mL PLL(20)-
g[3.5]-PEG(5) (SuSoS) and 10 mg/mL BSA-A7906 (Sigma-Aldrich). 
 
Figure 6: Experimental setup of the lab-based prototype. 
Fig. 6 shows the experimental setup used to perform the evaluations 
of urine samples. In this set-up, an external syringe pump is 
employed to pump fluids. A dual mode injector valve is used to load 
the samples to be tested in line with the neutral PBS buffer. During 
the experiment, first the buffer is flown to establish the baseline, 
then the clinical sample, followed by the buffer again to wash away 
any nonspecific binding. The sensor chip is squeezed under a home-
mode PDMS microfluidic channel. The light source is an 850 nm SLED. 
The signal is collected via a CMOS camera, which is connected to the 
computer to analyse the detected signal. 
A series of healthy and non-healthy urine samples were selected for 
experimental test. Apart from testing the lab prototype, the use of 
actual urine samples also allows us to evaluate the effect of 
nonspecific binding. The samples were pumped in the microflow cell 
at a rate of 10 µL/min for 20 minutes. Results from four sensors on 
the chip were analysed. 
 
 
Figure 7: Spectral shift due to healthy (a) and non-healthy (b) 
samples. 
 
Fig. 7a and 7b show the real-time interaction of healthy and non-
healthy urine samples with the anti-LAM molecules immobilised on 
the SiN sensors. First, 1x PBS (pH = 7) was administered to the 
sensors. After stabilisation of the signal, 200 μl of a healthy or non-
healthy urine sample was injected onto the sensors.  
 
In the case of healthy samples, initially a high spectral shift was 
encountered due to buffer exchange. This high spectral shift was only 
temporary and started to return back after a while since no 
LAM/anti-LAM binding was occurring. When 1x PBS was injected 
afterwards, the spectral shift moved back to a very low value (220 
pm) as compared to the initial shifted value. The spectral shift did not 
completely return back to its starting value and this can be attributed 
to nonspecific binding of residuals present in the urine samples to 
the sensors surface. 
 
In the case of non-healthy samples, a high increase in the spectral 
shift was encountered due to buffer effect. However, afterwards, 
when the 1x PBS was injected, a high permanent spectral shift 
compared to its initial value was encountered. This is due to the fact 
that LAM was present in the urine and it efficiently bound to the anti-
LAM immobilised on the sensor surface. In Fig. 7b, the non-healthy 
sample caused a permanent spectral shift of about 6 nm.  
 
Sample Type Spectral Shift 
Healthy Sample # 1 0.75 nm 
Healthy Sample # 2 0.85 nm 
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5  
Please do not adjust margins 
Please do not adjust margins 
Healthy Sample # 3 0.22 nm 
Healthy Sample # 4 0.50 nm 
Non-Healthy Sample # 1 6.00 nm 
Non-Healthy Sample # 2 5.50 nm 
Non-Healthy Sample # 3 7.00 nm 
Non-Healthy Sample # 4 4.00 nm 
Table 1: List of the spectral shift due to series of healthy and non-
healthy samples. 
A series of four healthy urine samples and four non-healthy urine 
samples were measured. The results are summarised in Table 1. A 
maximum of 0.85 nm in permanent spectral shift was obtained from 
healthy samples. The non-healthy samples caused a minimum 
permanent spectral shift of 4 nm and a maximum permanent 
spectral shift of 7 nm, which depends on the concentration of the 
LAM present in the urine samples. The permanent spectral shift 
obtained due to non-healthy samples is very high compared to the 
permanent spectral shift obtained due to the healthy samples. 
Moreover, as can be noticed from Fig. 7a and 7b, the shape of the 
sensorgrams in both cases is also very different: while the sample is 
still being injected, the spectral shift already starts to decrease for 
the healthy sample, which is not the case for the non-healthy sample.  
Finally, the sensorgrams also show that an assay time of 10 to 15 
minutes is feasible. 
Microfluidics cartridge 
Microfluidic cartridge bodies were injection-moulded in COC (cyclo-
olefin-polymer, tradename Topas). This allows for a cost-effective 
large-scale production, so that the cartridges can be made cheap 
enough to be disposable. 
For the integrated cartridge design, an injection moulding platform 
of a microscopy slide format with footprint of 75.5mm x 25.5mm was 
chosen. This format provides an easy to handle size on which all 
relevant fluidic and detection functionalities were accommodated, 
allowing for a high integration density with various functional 
elements for such a disposable cartridge. 
A photograph of a microfluidic cartridge with the integrated photonic 
chip is depicted in Fig. 8. 
 
Figure 8: Assembled microfluidic cartridge. 
For the inlet of the urine sample and required reagents, the 
integrated cartridge includes female Luer interfaces being 
compatible with standard syringes, as commonly used. 
An integrated filter ensures the retention of coarse components 
from the urine sample and an integrated air bubble trap retains 
undesirable air bubbles. At the end of the fluidic path, a reservoir for 
easy liquid waste handling is placed, followed by an air vent to allow 
air to escape from the cartridge when the waste reservoir fills up. 
With respect to the integration of the sensor chip, there is an 
appropriately designed recess on the top, while the rest of the 
cartridge is designed to leave parts of the chip exposed for easy 
optical access. Indeed, light is coupled into and out of the chip 
through grating couplers, and these need to stay exposed. 
 
 
Figure 9: Cross section (bottom) through microfluidic cartridge 
along the section A-A (indicated in top figure).  
Fig. 9 shows an intersection through the sensor area of the 
microfluidic cartridge. Note that the photonic chip is positioned 
upside down and that the optical detection is performed from the 
bottom side. 
Integrated readout instrument 
The realised readout instrument is shown in Fig. 10. The POC 
platform includes the optical readout, the pumping unit interfacing 
with the cartridge, and a touch screen with the user interface. The 
size of the instrument is determined by the choice of using vertically 
oriented syringes to load the samples and the buffers. 
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Figure 10: Integrated readout instrument. 
When designing the concept of this instrument, importance was 
given to flexibility, the possibility to test alternatives to specific parts, 
ease of assembly, ease of shipment and system installation at test 
sites. Likewise it should be noted that – although the readout 
architecture is selected to be low-cost - the prototype instrument 
design is also not yet optimised for cost. For example, the integration 
of the full Windows-PC including a high-res touch screen certainly 
adds up to the cost of the system, but also offers flexibility to update 
software in a late stage of the development (testing) cycle. 
The optical readout unit (Fig. 11) contains the light source as well as 
the light sensor to interrogate the optical biosensor chip. The unit is 
mounted upside down in the bottom part of the instrument. The light 
source (SLED) and the detector (CMOS sensor) are both commercial 
off-the-shelf components, coupled to a custom lens system. 
 
Figure 11: Optical readout module (upside down). 
Three syringe pumps are integrated in the readout instrument (Fig. 
12). Each pump has a stepper motor directly driving a piston up and 
down. The piston pushes the plunger of the syringe downwards, 
transferring the contents of the syringe (buffer, sample, ...) to 
cartridge. As the distance between the syringes is small, the piston 
axis is not in line with the stepper motor axis, but parallel. A dry 
bearing system is used to guide the piston up and down. The piston 
also includes a pressure sensor, to detect mechanical contact 
between the piston head and the syringe plunger. To increase 
confidence in the measurements, an extra flow monitoring system 
was also installed, consisting of a separate camera system to image 
the fluidic channel to perform bubble detection. 
 
Figure 12: Pump unit. 
Custom software was written to reliably identify the position of the 
output grating couplers in the images captured by the CMOS sensor. 
The intensities of these spots are then used in a fitting procedure, 
which allows us to track the position of the peak wavelength as a 
function of time. 
Fig. 13 shows a simple proof-of-concept sensing experiment on the 
instrument using the actual microfluidic cartridge, which measures 
the physical adsorption of BSA on an unfunctionalised sensor chip. 
 
Figure 13: Physical adsorption of BSA using an unfunctionalised 
cartridge. 
Biosensing with the integrated readout 
instrument 
Finally, this setup was used to perform biosensor experiments using 
functionalised chips. As a model system to test the prototype, the 
immunosensing of the C-reactive protein (CRP) biomarker was 
chosen. CRP is a widely used biomarker in patients that plays an 
essential role as an early indicator of inflammation and infection, and 
is also used as an indicator of prognosis for cardiovascular diseases 
[16]. CRP concentration in serum in healthy conditions is lower than 
10 μg/mL and it can increase up to 200 μg/mL in case of inflammation 
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or infections. CRP can be detected through the interaction with its 
specific antibody.  
Monoclonal antibody anti-human C-reactive protein C7 produced in 
mouse and human CRP was purchased from HyTest (Finland) and BBI 
Solutions (UK), respectively. All chemical reagents were purchased 
from Sigma-Aldrich (Germany). 
A concentration of 50 µg/mL of anti-CRP in phosphate buffer saline 
(PBS; 10 mM phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4) was 
immobilised onto the surface of the chip through physical 
adsorption, followed by a 10 mg/mL of bovine serum albumin 
solution (BSA) to block the free sensor surface areas. Milli-Q water 
(Millipore, US) was used as running buffer for the immobilisation and 
blocking steps. For the CRP protein detection, the running buffer was 
changed to PBS to ensure the optimal conditions for the 
immunosensing interaction, as well as to maximise the stability of 
the bioreceptor layer.   
In a physical immobilisation strategy, it is not possible to remove the 
bound CRP protein to the antibody due to its weak attachment to the 
sensor surface and thus an additive immunosensing assay was 
employed to establish the analytical calibration curve of the CRP 
detection. To study the biointeraction between CRP and its specific 
antibody, successive dilutions of increasing CRP concentrations (50, 
100, 250, 500 and 750 ng/mL) were flowed over the sensor area. A 
direct relationship between the concentration and the sensor 
response can be observed (Fig. 14). Furthermore, the specificity of 
the immunoassay was analysed by injecting a control of 1000 ng/mL 
of BSA instead of CRP, resulting in a negligible response of the sensor, 
as shown also in Fig. 10. 
 
Figure 14: Real-time monitoring of different CRP concentrations and 
BSA as a control with the biosensor instrument.  
 
As shown in Fig. 15, a detection curve was obtained by plotting the 
accumulated response signal as a function of the accumulated CRP 
concentration. The limit of detection (LOD) was determined from the 
calibration curve as three times the standard deviation of the signal. 
The resulting LOD was 19.478 ng/mL (R2 = 0.9701) which 
theoretically corresponds to the lowest detectable CRP 
concentration. These results indicate that the integrated instrument 
and the designed photonic sensor could be used as an effective 
biosensor for CRP detection as the concentration of this biomarker 
when related to infection or disease is much higher than the one 
obtained. 
 
Figure 15: Calibration curve for the detection of CRP in PBS. 
 
Conclusions 
We presented an integrated sensor platform that allows for low-cost 
detection of various biomarkers. The sensor chip with integrated 
spectral filter eliminates the need for an expensive tuneable laser, 
such that a cheaper broad-band light source can be used. A 
technology to integrate this chip into a microfluidic cartridge was 
presented, together with the development of a dedicated readout 
instrument. We presented proof-of-concept results for detection of 
LAM in actual clinical urine samples as well as for the detection of 
CRP. These results show the feasibility of using this system as a 
promising platform technology to detect different kinds of 
biomarkers using a cheap readout instrument. 
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